Conditions: Gout
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 12
Healthy volunteers: no

Brief summary:
This is a Phase 1b, randomized, open-label, drug-drug interaction study in adult male subjects with gout. It is designed to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of RDEA3170 or allopurinol alone and in combination in the fed state.

Detailed description:

Arms:
arm 1: RDEA3170 qd (once daily), RDEA3170 + allopurinol qd, allopurinol qd arm 2: allopurinol qd, RDEA3170 + allopurinol qd, RDEA3170 qd

Interventions: intervention 1: RDEA3170 10 mg intervention 2: allopurinol 300 mg
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: